TIDMTRX

RNS Number : 5437X

Tissue Regenix Group PLC

05 May 2021

Tissue Regenix Group plc

("Tissue Regenix" or "the Group")

Grant of share options

Tissue Regenix (AIM: TRX), the regenerative medical devices company, announces that Daniel Lee, Chief Executive Officer, and David Cocke, Chief Financial Officer, have each been granted an award of restricted share units ("RSUs") with respect to ordinary shares in the capital of the Company ("Ordinary Shares") under the existing Tissue Regenix Share Incentive Plan.

Daniel Lee has been awarded 28,321,603 RSUs and David Cocke has been awarded 14,649,105 RSUs, where each RSU that vests shall represent the right to receive payment of one Ordinary Share. The exercise price of the RSUs is 0.1p per Ordinary Share. The RSUs are subject to continued service over a period of three years and satisfaction of customary performance conditions relating to growth in total shareholder return, annual revenue targets, annual profitability targets and personal performance targets.

Following the grant of these options, Daniel Lee and David Cocke hold options over a total of 28,321,603 and 14,649,105 RSUs respectively representing 0.4% and 0.2% of the current issued share capital respectively.

For more information:

 
 Tissue Regenix Group plc                                    www.tissueregenix.com 
  David Cocke, Chief Financial Officer                             Via Walbrook PR 
 
 Stifel Nicolaus Europe Limited (Nominated Adviser         Tel: +44(0)20 7710 7600 
  and Broker) 
  Ben Maddison / Alex Price 
 Walbrook PR Ltd                                          Tel: +44 (0)20 7933 8780 
  Alice Woodings / Paul McManus                       TissueRegenix@walbrookpr.com 
 
 

About Tissue Regenix ( www.tissueregenix.com )

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL(R)') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn-out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In August 2017 Tissue Regenix acquired CellRight Technologies(R), a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and soft tissue scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, foot & ankle, dental, and sports medicine surgical procedures.

Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMRs") and persons closely associated ("PCA") with them.

 
  1   Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                   Daniel Lee 
     ---------------------  ------------------------------------------- 
 2    Reason for the notification 
     ------------------------------------------------------------------ 
 a)   Position/status        CEO 
     ---------------------  ------------------------------------------- 
 b)   Initial notification   Initial notification 
       /Amendment 
     ---------------------  ------------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ------------------------------------------------------------------ 
 a)   Name                   Tissue Regenix Group plc 
     ---------------------  ------------------------------------------- 
 b)   LEI                     213800PNOD5UHQUFJI36 
     ---------------------  ------------------------------------------- 
 4    Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of 
       transaction; (iii) each date; and (iv) each place where 
       transactions have been conducted 
     ------------------------------------------------------------------ 
 a)   Description            Restricted share units ("RSUs") with 
       of the financial       respect to ordinary shares in the capital 
       instrument,            of the Company of 0.1p 
       type of instrument 
     ---------------------  ------------------------------------------- 
 b)   Identification         GB00B5SGVL29 
       code 
     ---------------------  ------------------------------------------- 
 c)   Nature of the          Issue of options 
       transaction 
     ---------------------  ------------------------------------------- 
 d)   Price(s) and           Volume(s): 
       volume(s)              28,321,603 RSUs 
                              Price: 0.1 pence per RSU 
     ---------------------  ------------------------------------------- 
 d)   Aggregated 
       information             28,321,603 
       - Aggregated            GBP28,321.60 
       volume 
       - Price 
     ---------------------  ------------------------------------------- 
 e)   Date of the            4 May 2021 
       transactions 
     ---------------------  ------------------------------------------- 
 f)   Place of the           Outside of a trading venue 
       transaction 
     ---------------------  ------------------------------------------- 
 
 
  1   Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                   David Cocke 
     ---------------------  ------------------------------------------- 
 2    Reason for the notification 
     ------------------------------------------------------------------ 
 a)   Position/status        CFO 
     ---------------------  ------------------------------------------- 
 b)   Initial notification   Initial notification 
       /Amendment 
     ---------------------  ------------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ------------------------------------------------------------------ 
 a)   Name                   Tissue Regenix Group plc 
     ---------------------  ------------------------------------------- 
 b)   LEI                     213800PNOD5UHQUFJI36 
     ---------------------  ------------------------------------------- 
 4    Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of 
       transaction; (iii) each date; and (iv) each place where 
       transactions have been conducted 
     ------------------------------------------------------------------ 
 a)   Description            Restricted share units ("RSUs") with 
       of the financial       respect to ordinary shares in the capital 
       instrument,            of the Company of 0.1p 
       type of instrument 
     ---------------------  ------------------------------------------- 
 b)   Identification         GB00B5SGVL29 
       code 
     ---------------------  ------------------------------------------- 
 c)   Nature of the          Issue of options 
       transaction 
     ---------------------  ------------------------------------------- 
 d)   Price(s) and           Volume(s): 
       volume(s)              14,649,105 RSUs 
                              Price: 0.1 pence per RSU 
     ---------------------  ------------------------------------------- 
 d)   Aggregated 
       information             14,649,105 
       - Aggregated            GBP14,649.10 
       volume 
       - Price 
     ---------------------  ------------------------------------------- 
 e)   Date of the            4 May 2021 
       transactions 
     ---------------------  ------------------------------------------- 
 f)   Place of the           Outside of a trading venue 
       transaction 
     ---------------------  ------------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHDKQBQDBKBOPK

(END) Dow Jones Newswires

May 05, 2021 02:00 ET (06:00 GMT)

Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jun 2021 to Jul 2021 Click Here for more Tissue Regenix Charts.
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jul 2020 to Jul 2021 Click Here for more Tissue Regenix Charts.